Ebola vaccine induces T cell cross-reactivity against Bundibugyo virus in humans
The current Bundibugyo Ebola virus (BDBV) outbreak in the Democratic Republic of the Congo is the second largest Ebola outbreak worldwide, with over 6,000 confirmed cases and a 48% fatality rate. There is currently no approved BDBV vaccine.
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
Common leukemia mutation derails protein positioning during cell division, study reveals
-
What happens when brain tumors return? International study tracks genetic changes behind recurring cancers
-
Insights about cachexia, one of cancer's most common complications, hiding in routine patient data
-
Most patients won't endorse AI medical responses without a clinician's review, study finds
-
Cancer-promoting protein also helps engineered immune cells fight tumors in lab tests
-
Herpes 'remedies' sold on Amazon and Walmart pose public health risk, FDA warns
-
Neighborhood conditions linked to childhood cancer survivors' long-term health
-
Phenobarbital shows no clear advantage over diazepam for alcohol withdrawal, large study finds